Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 417 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 417 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $27.55, for a total transaction of $11,488.35. Following the transaction, the insider owned 63,443 shares of the company’s stock, valued at $1,747,854.65. This represents a 0.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Tuesday, May 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $29.36, for a total transaction of $186,377.28.
• On Wednesday, May 13th, David Malcom Rodman sold 14,056 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.58, for a total transaction of $401,720.48.
• On Monday, May 11th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $29.71, for a total transaction of $64,500.41.
• On Friday, April 17th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $31.33, for a total transaction of $13,033.28.
• On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.66, for a total transaction of $175,585.68.
• On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.54, for a total value of $373,099.32.
• On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total value of $59,414.60.
• On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $27.37, for a total value of $173,744.76.
• On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total value of $369,163.08.
• On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total value of $58,269.64.

Mineralys Therapeutics Stock Performance

Shares of MLYS opened at $26.03 on Wednesday. The stock has a 50 day moving average price of $27.05 and a 200 day moving average price of $32.37. Mineralys Therapeutics, Inc. has a one year low of $12.59 and a one year high of $47.65. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -12.70 and a beta of 0.49.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.04. On average, analysts predict that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of institutional investors have recently bought and sold shares of MLYS. Bank of America Corp DE grew its stake in shares of Mineralys Therapeutics by 11.5% in the 1st quarter. Bank of America Corp DE now owns 1,100,372 shares of the company’s stock valued at $29,809,000 after buying an additional 113,092 shares during the period. Stempoint Capital LP grew its position in Mineralys Therapeutics by 83.9% in the first quarter. Stempoint Capital LP now owns 533,378 shares of the company’s stock worth $14,449,000 after acquiring an additional 243,329 shares during the period. ADAR1 Capital Management LLC increased its stake in Mineralys Therapeutics by 13.5% during the first quarter. ADAR1 Capital Management LLC now owns 154,686 shares of the company’s stock worth $4,190,000 after acquiring an additional 18,455 shares during the last quarter. California State Teachers Retirement System increased its stake in Mineralys Therapeutics by 41.3% during the first quarter. California State Teachers Retirement System now owns 61,266 shares of the company’s stock worth $1,660,000 after acquiring an additional 17,918 shares during the last quarter. Finally, Rock Springs Capital Management LP raised its position in Mineralys Therapeutics by 2.8% in the first quarter. Rock Springs Capital Management LP now owns 439,751 shares of the company’s stock valued at $11,913,000 after purchasing an additional 12,155 shares during the period. 84.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on MLYS. Jefferies Financial Group restated a “hold” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Wall Street Zen lowered shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. TD Cowen initiated coverage on Mineralys Therapeutics in a report on Monday, April 27th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Tuesday, April 21st. Finally, Bank of America lifted their price objective on Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Mineralys Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $49.33.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.